Imatinib mesylate has revolutionized the treatment of chronic myeloid leukemia (CML). By targeting the BCR-ABL protein kinase, imatinib inhibits the molecular basis of CML. Imatinib has demonstrated remarkably high shortterm efficacy. Recently imatinib has shown to prolong the progression-free survival of CML patients. 1 However, complete molecular remissions under imatinib therapy remain rare events 2 and it seems unlikely that any patient will prove to be cured. Thus, allogeneic stem cell transplantation (SCT) remains the only curative option. At present, the high incidence of treatment-related mortality after allogeneic SCT on the one hand and the lowtoxicity profile of imatinib on the other have to be taken into account when treating CML patients. Currently, it is unclear how best to incorporate imatinib and allogeneic SCT into CML trials. In some trials, allogeneic SCT is postponed until clearance of BCR-ABL cells to a certain degree or even to the time after failure or resistance to imatinib, while other trials use imatinib as an 'adjuvant' treatment after allogeneic transplantation or as relapse therapy with or without donor lymphocyte infusion (DLI).
Recently, there have been reports that resistance to imatinib due to clonal evolution results in refractory leukemia and/or disease progression. 3, 4 The aim of this study was to investigate whether clinical response or resistance to pretransplant imatinib therapy had an influence on transplantation results. Therefore, we retrospectively analyzed the outcome of all patients transplanted at our center who had received imatinib prior to transplantation with respect to development of clinical resistance. In total, 29 CML patients were included in this analysis. The majority of these were late stage CML patients. There were no significant differences with respect to pretransplant risk factors 5 between the imatinib resistant and the responding groups (Table 1) . For evaluation of response to therapy, all cases underwent routine chromosome banding analysis according to standard protocols and FISH analysis for BCR-ABL-rearrangement on interphase nuclei on bone marrow smears. Clinical resistance to imatinib was defined as (1) primary cytogenetic unresponsiveness or (2) detection of increasing percentage of Ph þ metaphases and/or BCR-ABL positive interphase nuclei in FISH analysis in the bone marrow of CML patients under ongoing imatinib therapy.
The results of this study are depicted in Table 1 . No differences were detectable concerning neutrophil engraftment, incidences of acute GvHD grades II-IV, or extensive chronic GvHD between the two groups. Imatinib resistance resulted in a higher transplant-related mortality (TRM þ 100 days: 25 vs 0%, P ¼ 0.025), relapse rate (25 vs 6%, P ¼ 0.025), and inferior overall survival at 2 years (32 vs 72%, P ¼ 0.016). The poor outcome of the imatinib resistant group may be due in part to transformation into a more aggressive, refractory leukemic clone 3,4 associated with loss of graft-versus-leukemia effect.
Taken together, our data are suggestive that imatinib resistance may be an adverse prognostic factor for CML patients undergoing allogeneic SCT. Larger patient numbers and prospective trials are necessary to define the role of imatinib resistance -especially in early stage CML -as this may alter the treatment strategy of CML. 
